Page 70 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology An update on SLE

76. Egner W. The use of laboratory tests in the diagnosis of SLE. erythematosus - 2013 update. Bull Hosp Jt Dis (2013).
J Clin Pathol. 2000;53(6):424-432. 2013;71(3):208-213.
doi: 10.1136/jcp.53.6.424 81. Tanaka Y. State-of-the-art treatment of systemic lupus
erythematosus. Int J Rheum Dis. 2020;23(4):465-471.
77. Lehmann P, Homey B. Clinic and pathophysiology of
photosensitivity in lupus erythematosus. Autoimmun Rev. doi: 10.1111/1756-185X.13817
2009;8(6):456-461.
82. Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects
doi: 10.1016/j.autrev.2008.12.012 on rash and arthritis: Impact of the type I interferon
gene signature in the phase IIb MUSE study in patients
78. Cai T, Zhao J, Yang Y, Jiang Y, Zhang JA. Hydroxychloroquine
use reduces mortality risk in systemic lupus erythematosus: with systemic lupus erythematosus. Lupus Sci Med.
A systematic review and meta-analysis of cohort studies. 2018;5(1):e000284.
Lupus. 2022;31(14):1714-1725. doi: 10.1136/lupus-2018-000284
doi: 10.1177/09612033221129774 83. Singh JA, Shah NP, Mudano AS. Belimumab for systemic
lupus erythematosus. Cochrane Database Syst Rev.
79. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P,
Khamashta MA. Clinical efficacy and side effects of 2021;2(2):CD010668.
antimalarials in systemic lupus erythematosus: A systematic doi: 10.1002/14651858.CD010668.pub2
review. Ann Rheum Dis. 2010;69(1):20-28.
84. Leandro M, Isenberg DA. Rituximab - the first twenty years.
doi: 10.1136/ard.2008.101766 Lupus. 2021;30(3):371-377.
80. Belmon HM. Treatment of systemic lupus doi: 10.1177/0961203320982668

Volume 9 Issue 3 (2025) 62 doi: 10.36922/EJMO025090042